After Apple (AAPL) announced that it will be reintroducing a Blood Oxygen feature for certain Apple Watch models via a software update, BTIG noted that the firm believes that the litigation path between Masimo (MASI) and the iPhone maker continues. The firm, which does not think this U.S. Customs ruling and Apple software update necessarily impacts the legal arguments, continues to view any legal wins as “a call option” for Masimo and sees a buying opportunity on today’s weakness. The firm keeps a Buy rating and $198 price target on Masimo, which is down about 5% to $148.64 in Thursday morning trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MASI:
- Masimo Corp. Earnings Call Highlights Growth and Resilience
- Cautious Outlook on Masimo: Hold Rating Amid Mixed Financial Signals and Strategic Adjustments
- Masimo price target raised to $210 from $200 at Piper Sandler
- Masimo Corp. Reports Strong Q2 2025 Growth
- Masimo Reports Strong Q2 2025 Financial Results